Regulatory & Legal

With $65M in new funding and a new CEO, Duos is betting big on a $200M NVIDIA GPU deal to become a key player in the booming Edge AI infrastructure market.

With a soaring stock and a breakthrough CAR-T therapy, Immix Biopharma is set to capture investor attention. What's behind the hype for its lead drug, NXC-201?

Daxor reports a transformative year with 45% revenue growth, a new FDA-cleared portable analyzer, and a full pivot to a high-growth medtech company.

With a 10-K filed and new acquisitions, THC Therapeutics is fighting to shed its obscure market status and build a vertically integrated cannabis powerhouse.

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

The aerial firefighting giant lands a major DOI contract for Alaskan transport, signaling a strategic shift into year-round government logistics.

The neurohealth firm surpassed revenue estimates and hit positive cash flow, but a dynamic competitive landscape and CEO transition loom ahead of its earnings call.

A new deal brings Nanox's low-radiation, cost-effective Nanox.ARC to orthopedic clinics, aiming to reshape point-of-care diagnostics in the region.

A new partnership between Dstillery, Keynes, and The Trade Desk cuts a 48-hour workflow to 5 minutes, heralding a new era of autonomous AI in advertising.

As Akebia heads to a major conference, investors watch its Vafseo launch, new rare disease pipeline, and path to profitability. Here's what's at stake.

As shadow AI and autonomous agents create huge risks, Teramind's new platform offers total visibility to help firms innovate without sacrificing security.

A new poll shows 81% of South Carolinians back energy choice for industry, but critics fear it could leave homeowners paying more for power.

As SIGA prepares to unveil its 2025 financials, investors are focused on the future of its Tpoxx contracts and its role in global biodefense strategy.

A new survey reveals a silent public health crisis as millions of Canadians face chronic sleep loss, with many admitting to driving while dangerously tired.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.

Axxess's upcoming conference tackles AI's role in home health, unveils a new leadership certification, and honors an industry titan. Here's what it means.

The digital asset giant is delisting from Toronto to streamline costs, a move that reshapes its buyback plan and how Canadian investors trade its stock.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

A new trial for a cell therapy targeting a rare eye disease offers hope, driven by a patient-advocate's journey and with potential to treat common AMD.

Esperion's $75M+ deal for Corstasis and its novel nasal diuretic, Enbumyst, targets a $4B market and a new era of at-home edema management.